Funder: National Institutes of Health
Due Dates: April 10, 2025 | August 11, 2025 (final)
Funding Amounts: Up to $3 million/year in direct costs; max project period 5 years (2 years UG3, 3 years UH3)
Summary: Supports preclinical and clinical research to develop medications for preventing and treating substance use disorders and overdose, advancing candidates toward FDA approval.
Key Information: Applicants must propose both UG3 (milestone-driven) and UH3 phases; foreign and domestic organizations eligible; clinical trials optional.